Sunday, November 23, 2014 12:07:01 AM
Eli Lilly acquired Amyvid Test from Avid Radiopharmaceuticals for a whopping $800 million. ($300 million + $500 million in backend payments).It was not approved by FDA when they acquired. The Amyvid Test has lots of flaws despite it is FDA approved and yet it does not accurately diagnose patients with Alzeimer's disease.It costs patients lots of money through PET and MRI scans and after that further tests with limited accuracy. These machines are very expensive and are not readily available across US. Lympro is further ahead of Amyvid and is less expensive.
Read article link below for Amyvid Vs Lympro by Jason Napodano.
Next, Mark your Calendar for J P Morgan healthcare conference January 12-15 to be held in San Francisco.The Lympro will no longer be AMBS asset IMO because Gerald will be sitting on boatload of cash.
Good Luck to All...!
$AMBS
http://seekingalpha.com/article/1347691-amarantus-lympro-could-be-a-game-changer-for-alzheimers-diagnosis
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM